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ABSTRACT
ROR/RZR is an orphan nuclear receptor that has no
known ligand in the ‘classical sense’. In the present
study we demonstrate that RORα is constitutively
expressed during the differentiation of proliferating
myoblasts to post-mitotic multinucleated myotubes,
that have acquired a contractile phenotype. Exogenous
expression of dominant negative RORα1∆E mRNA in
myogenic cells significantly reduces the endogenous
expression of RORα1 mRNA, represses the accumu-
lation and delays the activation of mRNAs encoding
MyoD and myogenin [the muscle-specific basic helix–
loop–helix (bHLH) proteins] and p21Waf-1/Cip-1 (a cdk
inhibitor). Immunohistochemistry demonstrates that
morpho-logical differentiation is delayed in cells
expressing the ROR∆E transcript. Furthermore, the
size and development of mutlinucleated myotubes is
impaired. The E region of RORα1 interacts with p300,
a cofactor that functions as a coactivator in nuclear
receptor and MyoD-mediated transactivation. Consistent
with the functional role of RORα1 in myogenesis, we
observed that RORα1 directly interacts with the bHLH
protein MyoD. This interaction was mediated by the
N-terminal activation domain of the bHLH protein,
MyoD, and the RORα1 DNA binding domain/C region.
Furthermore, we demonstrated that p300, RORα1 and
MyoD interact in a non-competitive manner. In con-
clusion, this study provides evidence for a biological
role and positive influence of RORα1 in the cascade of
events involved in the activation of myogenic-specific
markers and cell cycle regulators and suggests that
crosstalk between the retinoid-related orphan (ROR)
nuclear receptors and the myogenic bHLH proteins
has functional consequences for differentiation.
INTRODUCTION
Members of the nuclear receptor superfamily bind specific DNA
elements and function as transcriptional regulators (1,2). This
group includes the ‘orphan receptors’ which have no known
ligands in the ‘classical sense’. The orphan receptor ROR/RZRα
(retinoic acid receptor-related orphan receptor) is closely related
to Rev-erbAα, RVR/Rev-erbβ/BD73 and Drosophila orphan
receptor E75A, particularly in the DNA binding domain (DBD)
and the putative ligand binding domain (LBD). ROR, Rev-erbAα
and RVR bind as monomers to an asymmetric (A/T)6RGGTCA
motif. ROR functions as a constitutive transactivator of gene
expression; in contrast, Rev-erbAα and RVR do not activate
transcription, mediate transcriptional repression and can repress
constitutive transactivation from this motif by RORα (3–9).
Three ROR/RZR genes have been identified. RORα encodes
four RORα isoforms, α1, α2 α3 and RZRα, which are
alternatively spliced products of the RORα gene and are
predominantly expressed in blood, brain, skeletal muscle and fat
cells (8,10). RORβ/RZRβ is expressed specifically in the brain
(11) and RORγ is found at high levels in skeletal muscle (12–14).
Although, RORα is expressed in skeletal muscle and myogenic
cells, its functional role has not been established. However,
evidence for a physiological/biological role of this group of
related but opposingly acting nuclear orphan receptors has come
from cell culture studies. Exogenous expression of Rev-erbAα
and RVR in muscle cells antagonistically regulates differentiation
and inhibits expression of the hierarchical myoD gene family and the
cdk inhibitor p21Waf-1/Cip-1 (15–17), which control muscle-specific
gene expression and cell cycle exit during myogenesis, respectively.
Furthermore, during myogenic differentiation, the expression of
Rev-erbAα and RVR mRNAs is repressed, hence, one of our
objectives was to elucidate the functional role of RORα in muscle
differentiation and to identify putative targets of RORα action in
muscle.
Muscle differentiation is the process whereby proliferating
myoblasts permanently exit the cell cycle and fuse to become
post-mitotic, multinucleated myotubes with a contractile phenotype,
that express myogenic markers (reviewed in 18,19). Insights into
this process have been provided by the identification of a group
of basic helix–loop–helix (bHLH) proteins encoded by the myoD
gene family (myoD, myf-5, myogenin and MRF-4/myf-6/herculin).
The products of the myoD gene family are muscle-specific
transactivators that can direct cell fate, repress proliferation and
activate differentiation and the contractile phenotype. The muscle-
specific bHLH proteins function at the nexus of command circuits
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that control the mutually exclusive events of division and
differentiation (reviewed in 18–20). Gene targeting studies have
suggested that while myoD and myf-5 are required for determination
(21), myogenin is specifically required for differentiation (22).
MyoD plays a dual role during myogenesis, activating both
muscle-specific gene transcription and promoting cell cycle exit
by inducing the expression of p21Waf-1/Cip-1, an inhibitor of
cyclin-dependent kinases and cellular proliferation (23–28).
Transactivation by MyoD involves: (i) the bHLH domain, that is
involved in both DNA binding and dimerization; (ii) the
heterodimerization of MyoD with the ubiquitously expressed
E2A gene products, E12 and E47 (27); (iii) the binding of
MyoD–E2A heterodimers to specific E-box motifs (CANNTG)
in muscle-specific enhancers (reviewed in 23–25); (iv) the
recruitment of the cofactors p300 and PCAF (29–31). The
cofactors, p300 and PCAF, are critical co-activators for MyoD
during myogenic commitment and differentiation. The N-terminal
activation domain of MyoD directly interacts with p300 and
recruits PCAF to form a ternary multimeric complex on promoter
elements (29,32). These events lead to hyperacetylated and
transcriptionally permissive chromatin. Moreover, p300 and
PCAF co-activate myoD-mediated transactivation of the p21
gene and are necessary for MyoD-mediated cell cycle arrest (32).
The transcriptional activity of MyoD is modulated by environ-
mental cues related to the concentration of growth factors,
receptors and oncogene products that promote cell division
(reviewed in 20). These agents inhibit the transcriptional activity
of MyoD by promoting: (i) the direct phosphorylation of the
bHLH region and/or the interaction with c-jun, which prevent
DNA binding; (ii) the activation of Id (inhibitor of differentiation)
expression, an HLH protein that lacks DNA binding ability and
functions as a dominant negative; (iii) the suppression/sequestering
of myogenic-specific transcription factors and cofactors.
Co-activators that mediate transactivation by nuclear receptors
include TIF1, ERAP160, RIP140 and p300/CBP. CBP (CREB
binding protein) and the parahomologue p300 are integrators of
multiple signal transactivation pathways. p300/CBP has been
shown to interact with both nuclear receptors and the transcriptional
machinery through multiple dimerization interfaces (33–35). The
involvement of the p300 family with orphan receptors, in
particular RORα, is an unexplored area of nuclear receptor
research.
To gain insight into the function of RORα1 in myogenesis we
used loss of function studies in myogenic cells as a tool to
elucidate the biological role of ROR in muscle. Ablation of
RORα expression in muscle cells was achieved by the exogenous
expression of a dominant negative RORα∆E. We observed that
these cells no longer express endogenous RORα and that the
onset/accumulation and expression of myogenic-specific
markers and cell cycle regulators had been altered. Furthermore,
the molecular basis of these effects involves direct interactions of
ROR with: (i) the myogenic-specific bHLH protein MyoD;




pCMX-RORα1 was kindly provided by V.Giguere. 5′-Primer
GMUQ253 (GCGGAATTCACCATGGAGTCAGCTCCGGC-
AGCC) and 3′-primer GMUQ254 (GCGGAATTCTTACCCAT-
CAATTTGCATTGC), containing EcoRI sites, were used to
synthesise the 523 amino acid full-length open reading frame of
RORα1. The product was end-filled and cloned into the SmaI site
of pBS (Stratagene). Plasmid pBS-ROR was digested with EcoRI
and the insert was subsequently cloned into pGEX-1N and pSG5
to form pGEX-ROR and pSG5-ROR. pGAL constructs were
prepared by subcloning in-frame restricted fragments of pBS-ROR,
with or without end-filling with Klenow, into the multiple cloning
site of vector pGAL0 (36) that contains the GAL4 DBD
sequence. Likewise, VP16 constructs of RORα1 were prepared
utilizing the multiple cloning site of pNLVP16. All pGAL and
pVP16 and pGEX clones have been checked and found to be in
the correct orientation. Double-stranded DNA sequencing shows
that the inserts were in the correct reading frame.
Construction of p300 plasmids. The CMVbp300 plasmid was
cleaved with BamHI between amino acids 595 and 1240 and the
resulting fragment was end-filled with and cloned into SalI-
cleaved/end-filled GAL0 plasmid. The p300 plasmid was cleaved
with ScaI and HindIII between amino acids 1030 and 2414 and
the resulting fragment was end-filled with and cloned into
SalI-cleaved/end-filled GAL0 plasmid. The N-terminal end of
p300 (amino acids 1–149) was produced by PCR, using primers
GM 320 (GCG GTC GAC ATA TGG CCG AGA ATG TGG TG)
and GM 322 (GCG GTC GAC TGA CTG CGT AGG ACC CTG)
and cloned into SalI-cleaved GAL0.
Cell culture and transient transfections
Mammalian two hybrid assay. Plasmids (1 µg of G5E1bCAT
reporter and 0.33 µg of GAL-N-CoR/RIP13 or p300) were
co-transfected/expressed in human choriocarcinoma JEG3 cells
with either VP16 or VP16–ROR (0.33 µg), then assayed with
respect to their ability to transactivate the reporter (G5E1bCAT).
Each 12-well dish of JEG3 cells (80% confluence) was transiently
transfected with plasmid DNA by the DOTAP/DOSPER (Boeh-
ringer Manneheim)-mediated procedure as described previously
(17).
CAT assays. The cells were harvested, normalised to protein
concentration and the CAT activity was measured as previously
described (37). Aliquots of the cell extracts were incubated at
37C with 0.1–0.4 mCi of [14C]chloramphenicol (NEN) in the
presence of 5 mM acetyl-CoA and 0.25 M Tris–HCl pH 7.8 and
analysed as described previously (15–17).
Stable transfections of C2C12. Myogenic C2C12 cells cultured in
20% FCS in DMEM to 40% confluence were co-transfected with
pCMV-NEO and either pSG5-ROR(1–235) or antisense
pSG5-ROR by the DOTAP-mediated procedure. The cells were
then grown for another 24 h to allow cell recovery and neomycin
resistance expression before G418 selection. After 14 days
selection with 400 µg/ml G418 in culture medium, stable
transfectants were cultured and maintained on 200 µg/ml G418
medium.
GST pulldown assay
pGEX-ROR was transformed into BL21 competent cells and
grown in LB medium. The GST fusion proteins were released
after IPTG induction and sonication. Lysates were bound to
equilibrated glutathione beads and then extensively washed and
left bound in NETN-1 buffer (0.5% NP-40, 1 mM EDTA, 20 mM
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Figure 1. Northern analysis of endogenous and exogenous RORα1 gene expression in native C2C12 cells and stably transfected RORα1 dominant negative C2C12
cells. (A) RORα gene expression is shown by RT–PCR with 28S rRNA as control from proliferating C2C12 (PMB) and 48 h differentiating (MT-2) C2C12 cells with
negative H2O control and DNA marker (Materials and Methods). (B) Analysis of RORα gene expression in C2C12 PMB and MT-2 cells by northern hybridization
of poly(A+) RNA with mouse RORα probe and 18S rRNA as control. (C) Proliferating C2C12 (PMB) cells (at <40% confluence) were cultured to confluence in growth
medium (GM) (20% FCS in DMEM) and thereafter the medium was replaced with differentiation medium (DM) (2% horse serum in DMEM). C2C12 cells were
differentiated for 2 days (MT-2) before harvesting for poly(A+) RNA extraction and analysis by northern blotting. Northern blots were probed with RORα1 showing
expression of the transfected dominant negative RORα1 gene. (D) Mouse RORα cDNA showing endogenous expression of RORα in transfected and untransfected C2C12
and (E) end-labelled 18S rRNA probe. (Materials and Methods gives details on transfection; this data is derived from three independent hybridisations of a single blot.)
Tris pH 8.0, 100 mM NaCl) with Complete protease inhibitor
cocktail (Boehringer Manneheim). GST–MyoD, GST–MyoD
N-terminus, GST–MyoD HLH and GST–MyoD C-terminus
have been described by Sartorelli et al. (29). pBluescript-p300,
pSG5-MyoD, EMSV-MyoD and pSG5-RORα1 were transcribed
and translated using the rabbit reticulolysate TnT kit according to
the manufacturer’s instructions (Promega). pGEX-ROR or
pGEX-MyoD beads or control pGSTag were incubated for 40 min
at room temperature with 35S-labelled proteins in NETN-1 buffer
with protease inhibitors and blocking agents (BSA and EtBr). The
beads were extensively washed three times with NETN-1. Bound
proteins were released by adding SDS–PAGE sample buffer and
heated to 95C for 10 min. The samples were run on miniprotean
10 or 12% SDS–PAGE gels (Bio-Rad) as described by Sartorelli
et al. (29).
Northern analysis
Total RNA was extracted by the acid guanidinium thiocyanate
phenol/chloroform method. Poly(A)+ RNA was further extracted
from total RNA using a mRNA isolation kit (Boehringer
Manneheim). Total RNA and poly(A)+ RNA were electrophoresed
in a formaldehyde gel and vacuum blotted onto Hybond N
membranes. The membranes were subsequently UV crosslinked
and dried in an incubator. Prehybridized membranes were
hybridized at 42C in 4× Denhardt’s solution, 45% formamide,
0.2% SDS, 0.1 mg/ml herring sperm DNA with random primed
DNA probes. After 2 days, the membranes were washed twice in
0.5–2× SSC, 0.1% SDS at 65C for 30 min. Autoradiographs
were scanned using a computer scanner and Adobe Photoshop.
Multiplex RT–PCR
C2C12 total RNA was reverse transcribed by Superscript reverse
transcriptase (Gibco) using random hexamers as primers. The
first strand product was subsequently amplified by touchdown
PCR using Taq polymerase and mouse RORα primers (L-primer,
GMUQ305, GCGAGATCTTTCATCAGCTTTGTGTTTGAA-
TTT; R-primer, GMUQ306, GCGAGATCTGGCGCGACATT-
TACCCATCGATTT) and 28S rRNA primers (L-primer, primer A,
ATCTAGTAGCTGGTTCCCTC; primer B, CCTCTAATCATT-
CGCTTTAC).
RESULTS
RORα is constitutively expressed in myogenic C2C12 cells
RORα has been shown to be expressed in skeletal muscle tissue.
This observation suggested that this protein may play a role
during mammalian myogenesis. Furthermore, the closely related
but opposingly acting Rev-erbA/RVR orphan nuclear receptors
are abundantly expressed in proliferating myogenic cells; however,
they are repressed during myogenic differentiation. To elucidate
the functional role of RORα in mammalian differentiation we
investigated the expression of RORα mRNA relative to 18S/28S
rRNA during myogenic differentiation in the mouse C2C12
myoblast cell line. Using the Genbank sequence of RORα to
design specific primers for mouse RORα amplification, we were
able to amplify the mouse RORα mRNA transcript from total
RNA isolated from proliferating and differentiated C2C12 cells
by multiplex RT–PCR (Fig. 1A). Subcloning and DNA sequencing
identified the expressed amplified product as RORα. We further
substantiated that RORα was constitutively expressed during
mouse myogenesis in culture by northern hybridisation analysis
of RNA isolated from proliferating and differentiated C2C12
cells (after 48 h serum withdrawal) (Fig. 1B). RORα is seen
transcribed as a double band in C2C12 as described in differentiated
P19 cells (9). This data demonstrated that the RORα mRNA
transcript was constitutively expressed during myogenic
differentiation in culture, relative to the 18S and 28S rRNAs
(Fig. 1A and B).
Exogenous dominant negative RORα expression delays the
activation and significantly reduces the expression of the
MyoD, myogenin and p21Waf-1/Cip-1 mRNAs
Proliferating C2C12 cells can be induced to biochemically and
morphologically differentiate into post-mitotic, multinucleated
myotubes by serum withdrawal in culture over a 48–96 h period.
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This transition from a non-muscle phenotype to a contractile
phenotype is associated with repression of non-muscle proteins
and activation of a structurally diverse group of genes. This gene
activation encodes a functional sarcomere responsible for the
major activity of this specialised cell type, i.e. contraction. The
events are characterised by the transition of the actin multigene
family. Non-muscle β- and γ-actins are down-regulated; in
contrast, the sarcomeric cardiac and skeletal α-actins are induced.
These isoform transitions correlate with the repression of cyclin
D1 (that is involved in the maintenance of the proliferative state),
induction of the muscle-specific bHLH gene myogenin and the
cdk inhibitor p21, that are involved in activation of muscle-specific
gene expression and permanent cell cycle arrest, respectively.
To understand the biological role of RORα1 during myogenesis
and to identify the putative target(s) of this orphan receptor in
muscle cells, we proceeded to examine the effect of knocking
out/ablating RORα function in myogenic C2C12 cells. We stably
(and independently) transfected C2C12 cells with dominant
negative and antisense RORα expression vectors with pCMV-
NEO. Stable transfectants were isolated as a polyclonal pool of
G418-resistant colonies (comprised of >20 individually resistant
colonies). The C2-RORα1(1–235) (also denoted as C2-ROR∆E)
cells were transfected with pSG5-ROR(1–235), which contained
a cDNA that only encoded amino acids 1–235. This dominant
negative construct lacked the entire E region and part of the
hinge/D region. This was chosen because the ‘staggerer’
phenotype in mice is due to a frameshift at amino acid 273 (38),
and McBroom et al. (39) reported that deletion of this region
preserved DNA binding but destroyed transactivation. Furthermore,
we noted that RORα1(1–235) was not sufficient to transactivate
gene expression from an optimal and single monomeric response
element linked to the basal tk-CAT reporter (data not shown). In
contrast, C2-RORα1 AS cells were transfected with the construct
pSG5-RORα1 AS, which contained the full-length RORα
transcript cloned in the antisense orientation.
The C2-RORα1(1–235) cells abundantly expressed the trans-
fected/exogenous transcript relative to the endogenous full-length
transcript (Fig. 1C and D, respectively). Interestingly, we
observed that the endogenous levels of the RORα mRNA
transcripts were significantly reduced in the C2-RORα1(1–235)
cells (Fig. 1D) relative to the equivalent levels of 18S rRNA
(Fig. 1E). Similarly, we detected the expression of the RORα
antisense transcript in the C2-RORα1 AS cells (Fig. 2A).
Down-regulation of the endogenous RORα transcripts is not
unexpected; mRNA pool sizes during myogenesis and in muscle
tissue are under strict control (40), a mechanism exists that senses
total output from exogenous and endogenous genes (37).
Furthermore, exogenous expression of a number of different
contractile protein transgenes in the mouse (e.g. myosin light
chain 2, troponin I fast and skeletal and cardiac actin) results in
a decline in the expression of the corresponding endogenous gene
(37,41–44).
To investigate the effect of exogenous dominant negative and
antisense expression on factors involved in the regulation of
myogenesis (e.g. MyoD and myogenin) and the control of the cell
cycle (e.g. cyclin D1 and p21). We isolated total RNA from normal,
C2-RORα1 AS and C2-RORα1(1–235) C2C12 proliferating
myoblasts (cultured in growth medium) and myotubes (after 96 h
serum withdrawal). RNA samples were northern blotted and
probed for 18S rRNA, MyoD, myogenin, cyclin D1 and p21 mRNA
expression. Northern analysis revealed important differences in the
Figure 2. Analyses of the functional role of RORα1 in muscle differentiation.
Proliferating C2C12 cells (at <40% confluence) are cultured to confluence in
growth medium (GM) (20% FCS DMEM) thereafter medium is replaced with
differentiation medium (DM) (2% horse serum DMEM). C2C12s were
differentiated for 1–4 days before being harvested for total RNA extraction and
northern hybridization. Multinucleated myotubes are formed after 4 days.
(A) Changes in gene expression observed in native C2C12 cells, and cells that
exogenously express RORα1 anti-sense and dominant negative transcripts,
before and after 96 h of differentiation. (B) Changes in gene expression
observed in native C2C12 cells, and cells that exogenously express the RORα1
dominant negative transcripts during the first 24 h of differentiation. (See
Materials and Methods for details on transfection.)
biochemical profile during myogenesis. In contrast to normal
C2C12 cells, the cells stably transfected with antisense RORα1
and dominant negative RORα1(1–235) had reduced steady-state
levels of MyoD mRNA after the induction of differentiation by
serum withdrawal (Fig. 2A). Furthermore, the level of myogenin
activation/induction was reduced in the stably transfected cell
lines. Interestingly, dominant negative RORα1 expression had a
stronger impact than expression of the antisense construct on
MyoD and myogenin expression (Fig. 2A). The induction/activation
of p21, which induces cell cycle exit, is also blocked in the
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Figure 3. Exogenous ROR∆E expression delays myotube development. Native C2C12 cells and C2-ROR∆E cells were harvested after 2–4 days in 2% horse serum
and were immunostained with a monoclonal antibody directed towards the fast isoform of the major thick filament protein, skeletal myosin heavy chain (MHC).
MHC-positive cells are stained red.
C2-RORα1(1–235) cell line (Fig. 2A). The altered biochemical
profile of mRNA expression in these stably transfected cells
correlated with the reduced ability of the C2-RORα1(1–235)
cells to differentiate in culture. This stable transfection analysis
suggested that RORα1 expression affected the expression of two
members of the muscle-specific bHLH gene family, myoD and
myogenin, and the cdk inhibitor, p21Waf-1/Cip-1, that are involved
in the activation of myogenic transcription and cell cycle exit,
respectively.
To determine whether the reduced steady-state levels of MyoD,
myogenin and p21 in the C2-RORα1(1–235) cell line were due
to a slower rate of differentiation, we conducted a time course
study. We isolated total RNA from C2 and C2-RORα1(1–235)
cells as proliferating myoblasts (PMB), confluent myoblasts
(CMB, harvested 24 h after harvesting of PMB cells), and 4, 8 and
24 h after serum withdrawal in DM (i.e. 4, 8 and 24 h after the
harvesting of the CMB sample in GM). These RNAs were
northern blotted and probed with 18S rRNA, myogenin, Id, cyclin
D1 and p21 (Fig. 2B). Northern analysis demonstrated that the
rate of terminal differentiation in the C2-RORα1(1–235) cell line is
delayed. The time of myogenin and p21 mRNA induction is delayed
by 8 and 24 h, respectively. Furthermore, the extent of myogenin and
p21 mRNA accumulation is reduced. The expression of these genes
that are responsible for initiating the differentiation process and
arresting the cell cycle, respectively, has been altered by dominant
negative expression of the RORα1 variant, suggesting that the
RORα1 orphan nuclear receptor has a positive influence on the
differentiation programme of myogenic cells.
To put these results into a morphological context we examined
the extent of myogenic conversion in the C2:ROR(1–235) cells
(denoted C2-ROR∆E cells in these experiments) relative to native
C2C12 cells; as measured by immunostaining with a monoclonal
antibody directed against a muscle-specific contractile protein
marker. The antibody is against the fast isoform of the major thick
filament contractile protein, skeletal myosin heavy chain (MHC).
MHC is associated with the contractile phenotype and is
expressed during the process of muscle differentiation. Immuno-
staining of native C2C12 cells after 48 h serum withdrawal (to
induce differentiation) in native C2C12 cells detected the
appearance of multinucleated myotubes (Fig. 3). In contrast,
ROR∆E cells after 48 h serum withdrawal lacked any significant
cellular immunostaining of MHC or myotube structures. After
96 h serum withdrawal significant immunostaining was observed
in both cell types; however, the native myotubes consistently
appeared larger, longer and more developed (Fig. 3). These
experiments are consistent with a delay in the time of and extent of
induction of the mRNAs regulating differentiation (e.g. myogenin)
and cell cycle exit (e.g. p21) observed in the northern analysis
above.
RORα1 directly interacts with the co-activator p300
Exogenous expression of the dominant negative ROR construct
in myogenic cells suggested that this member of the orphan
nuclear receptor family plays a positive role in myogenesis. We
then examined whether the constitutive transactivator, RORα1,
interacts with the cofactor, p300. This coactivator of nuclear
receptor- and MyoD-mediated transactivation is an important
regulator of cell cycle control (and p21 mRNA expression) during
muscle differentiation. CBP/p300 is a cofactor that interacts with
a host of transcription factors and mediates transcriptional
signalling, either through its histone acetylase activity or by
functioning as a bridge to recruit another coactivator(s) with
histone acetyltransferase activity, e.g. P/CAF (45,46). Regions of
p300 that have been demonstrated to interact with a variety of
transcription factors are schematically depicted in Figure 4A. In
particular, the N-terminal region of p300, between amino acids 1
and 149, has been shown to function as a receptor interaction
domain (RID) and to interact with a number of nuclear receptors,
including RAR, TR, RXR (33–35) and COUP-TF II (47).
To investigate whether RORα1 interacts with p300 in vivo, we
utilised the mammalian two-hybrid assay. We tested several
constructs of p300 to determine which domain/region of the
cofactor interacts with RORα1. The plasmids utilised in the
mammalian two-hybrid assay included p300-aa1–149,
p300-aa595–1240 and p300-aa1030–2414 that include regions of
the cofactor that interact with the nuclear receptors and other
known transcription factors (e.g. MyoD). These regions were
fused to form chimaera with the GAL4 DBD vector. The
GAL4–p300 fusion proteins were then tested for interaction with
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Figure 4. RORα1 interacts with the co-activator p300 in vivo and in vitro. RORα1 interacts with p300 in vivo. (A) Schematic representation of p300, highlighting
domains that interact with other transcription factors (50,57) and the domains linked to the GAL 4 DBD. (B) Analysis of the interaction of RORα1 with the p300
interaction domains GAL4–p300-aa1–149, GAL4–p300-aa595–1240 and GAL4–p300-aa1030–2414. (C) Interaction of GAL4–p300-aa1–149 with VP16–RORα1
chimaera. JEG3 cells were co-transfected with 1 µg of each GAL4 and VP16 chimera as indicated, with 3 µg of the reporter pG5E1bCAT. Results shown are mean
± SD and were derived from at least three independent experiments. Relative fold activation is expressed relative to CAT activity measured after transfection with the
appropriate GAL–p300 chimera and VP16 vector alone, arbitrarily set to 1.0. (D) Transactivation of MRE1–tkCAT by pSG5 RORα1 in COS-1 cells. MRE–tkCAT
was constructed by ligating the double-stranded Rev-erbAα monomeric response element to tkCAT. The clone was sequenced to contain only a single monomeric
binding site. pSG5-ROR(1–2294) was constructed by restriction digestion of pSG5-RORα1 with EcoRV + BamHI and SacI + BamHI and then end-filled by Klenow fragment
and religated. Transfection and CAT assay were as described previously. (E) GST–RORα1 on glutathione beads was incubated for 40 min with in vitro transcribed and
translated p300 in the presence of ethidium bromide and BSA. At the end of the incubation period, the beads were extensively washed and heated at 97C for 10 min in
sample dye and analysed by SDS–PAGE. Input was 25% of the amount used in the interaction reaction. GST–RORα1 interaction with p300 and the p300 RID.
a chimeric protein consisting of the full-length RORα1 cDNA
linked in-frame to the VP16 activation domain in the mammalian
cell line JEG3. VP16–RORα1 strongly interacted (∼20-fold)
with the N-terminal domain of p300 (amino acids 1–149)
(Fig. 4B). RORα1 did not interact with the other domains of
p300, indicating that RORα1 interacts only with the p300 RID.
In comparison, with RXRγ (in the presence of ligand), the
interaction of the N-terminal region of p300 with full-length
RORα1 is stronger [∼5-fold, and similar to that reported by
Chakravarti et al. (34)] (data not shown).
To identify the p300 interaction region in RORα1, we cloned
different regions of RORα1 into the VP16 vector and used the
mammalian two-hybrid assay to delimit the domain that mediated
the interaction with p300 (Fig. 4C). The results show that the
p300 RID interacts efficiently with RORα1 in the presence of an
intact E region, VP16–RORα1(295–523). The hinge/D region
and N-terminal/AB region of RORα1 had a negligible or limited
role in p300 binding (Fig. 4C). The importance of this region was
verified by demonstrating that deletion of the E region inhibited
the ability of RORα1 to transactivate a monomeric response
element (Fig. 4D).
The demonstration of an interaction between p300 and RORα1
in the in vivo mammalian two-hybrid assay strongly suggests that
these proteins may interact by a direct mechanism. However, this
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does not eliminate the possibility of an indirect mechanism in
which an additional factor(s) mediates this interaction. We tested
this hypothesis using a biochemical approach, the in vitro GST
pulldown assay, to confirm that p300 and RORα1 interact
directly. Glutathione–agarose immobilised GST–RORα1 was
tested for direct interaction with in vitro 35S-radiolabelled
full-length native p300 and the RID of p300. GST–RORα1
showed a direct interaction with full-length p300 (Fig. 4E) and the
p300 RID (Fig. 4E).
In conclusion, the in vivo and in vitro assays studies demonstrate
that ROR directly interacts with the cofactor p300, a critical
component of nuclear receptor- and MyoD-mediated transcription.
The efficiency of binding by the RID of p300 relative to the native
protein is weakly compromised; whether this reflects the
requirements of additional regions for binding is not clear and not
supported by the in vivo two-hybrid studies.
RORα1 directly interacts with MyoD: p300, RORα1 and
MyoD interact in a non-competitive manner
During the course of this investigation it has been reported that the
positive and negative effects of RXR and COUP-TF II on
myogenesis, respectively, involve novel interactions between the
DNA binding domain of these nuclear receptors and MyoD
(47,48). Furthermore, the observations that RORα1 interacted
with the cofactor p300, a coactivator of nuclear receptor- and
MyoD-mediated transactivation and an important regulator of cell
cycle control/p21 mRNA expression during muscle differentiation
(28–30,49), suggested that ROR could be functioning to regulate
MyoD activity/function by directly interacting with MyoD or be
part of a complex with MyoD and p300.
To determine the validity of this hypothesis we utilised the in vitro
GST pulldown assay, in which glutathione–agarose-immobilised
GST–MyoD was incubated with in vitro 35S-radiolabelled
full-length p300 and RORα1. This assay confirmed the interaction
of p300 with MyoD and clearly showed that RORα1 and MyoD
were indeed capable of a direct interaction in vitro (Fig. 5A).
Since MyoD has independently been shown to interact with
both p300 and RORα1, we investigated whether MyoD could
simultaneously interact with p300 and RORα1 in the GST pulldown
assay. Hence, we examined the ability of glutathione–agarose
immobilised GST–MyoD to interact with a mixture of in vitro
35S-radiolabelled full-length native p300 and RORα1 (Fig. 5A,
lane 7). We observed that GST–MyoD could simultaneously
pulldown p300 and RORα1. We then investigated whether
competitive binding between these interacting proteins was an
issue with respect to the formation of a putative ternary complex.
We examined the ability of increasing amounts of p300 (1, 3 and
10 µl; Fig. 5A, lanes 7–9) to affect the efficiency of interaction
between GST–MyoD and radiolabelled ROR (Fig. 5A). We did
not observe a reduction in the efficacy of binding among these
interacting proteins when the quantity of p300 was substantially
elevated, suggesting that these factors interact in a non-competitive
manner. Furthermore, we observed similar results when the quantity
of affinity resin was substantially reduced (data not shown).
The N-terminal activation domain of MyoD mediates the
interaction with the DNA binding domain of RORα1
To identify the domain within MyoD (Fig. 5B) that interacts with
RORα1, we examined the ability of a number of GST–MyoD
fusion chimaera containing functional subdomains of MyoD and
immobilised on glutathione–agrose beads [i.e. GST–MyoD
N-terminus (amino acids 1–100), GST–bHLH (amino acids
102–161) and GST–MyoD C-terminus (amino acids 162–318)]
to interact with 35S-radiolabelled RORα1 (Fig. 5B). The
N-terminus of MyoD linked to GST interacted strongly with in
vitro translated RORα1. In contrast, the GST–MyoD C-terminus
and GST–bHLH regions did not support any significant interaction
with RORα1. These experiments suggest that the N-terminal
activation domain of MyoD, which is represented by the first 100
amino acids of the protein, is required for RORα1 binding.
Interestingly, the N-terminal activation domain also mediates the
interaction with the coactivator, p300.
We then investigated whether the C-terminus of RORα1 was
necessary to support the interaction with MyoD. Hence, we
examined the ability of GST–MyoD immobilised on glutathione–
agarose beads to interact with 35S-radiolabelled RORα1 segments
between amino acid residues 1 and 294 and 1 and 235 (Fig. 5C).
It was observed that both C-terminally deleted fragments interact
very efficiently with MyoD in vitro. This data suggests that the
C-terminus of RORα1, which encodes the E region of ROR, is
not required for binding (Fig. 5C).
To delimit whether the N-terminal AB region or the DBD
mediated the interaction with MyoD in vitro, we examined the
ability of the fragments between amino acid residues 1 and 140 and
1 and 75 to interact with MyoD, relative to the native full-length
protein. In contrast to the ability of the region between 1 and 140
to support efficient binding, the fragment between amino acids 1
and 75 did not significantly bind MyoD (Fig. 5D).
We similarly examined the ability of the region between amino
acid residues 1 and 140, which encode the N-terminal AB region and
the C region/DBD, relative to the amino acid residues between 1 and
294, which encode the ABCD region of ROR, to interact with
various sub-domains of MyoD (Fig. 5E). We observed that the the
ABC region (amino acids 1–140) was sufficient to support the
interaction with MyoD. Furthermore, it was sufficient to mediate the
specificity of the interaction with the N-terminal region of MyoD
linked to GST (Fig. 5E). This suggested that the C region of ROR
was involved in mediating binding to MyoD.
Consistent with the observations above we also demonstrated
a direct interaction between the DBD of RORα1 and MyoD in the
GST pulldown assay. We showed that the C region/DBD alone
between amino acids 74 and 139 of ROR efficiently interacted with
the 35S-radiolabelled full-length MyoD, relative to native ROR
protein linked to GST and immobilised on glutathione–agarose
beads (Fig. 5F). The in vitro translated myoD product interacted with
similar efficiency with GST–RORα and GST–RORα(74–139).
This suggests that the C region of ROR that encodes the DBD
is necessary for the interaction with MyoD. Moreover, it suggests
that this region also functions as a dimerization interface.
DISCUSSION
Exogenous expression of the ROR∆E dominant negative expression
vector in C2 myogenic cells significantly reduced the expression
of MyoD, myogenin and p21 (and endogenous RORα) mRNA
levels after the induction of differentiation by serum withdrawal.
Futhermore, the extent of morphological differentiation as
assayed by immunocytochemistry was similarly effected. This
suggested that native RORα1 functions to positively regulate
myogenesis. These observations were entirely consistent with
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Figure 5. ROR and p300 directly interact with MyoD in vitro. (A) ROR and p300 were radiolabelled with [35S]methionine by in vitro transcription/translation and
assayed for their ability to interact with glutathione immobilised GST and GST–MyoD. Glutathione immobilised GST–MyoD protein was incubated with
35S-radiolabelled ROR and either 1, 3 or 10 µl of radiolabelled p300. In each pulldown, the input lanes represent ∼10% of the total protein. (B) The N-terminal acid-rich
activation domain of MyoD mediates the interaction with ROR II in vitro. GST pulldown showing an interaction between 35S-radiolabelled ROR and
glutathione–agarose immobilised GST and GST–MyoD N-terminus, GST–MyoD C-terminus and GST–MyoD bHLH. The input lanes represent ∼10% of the total
protein. (C) The E region of ROR is not required for MyoD binding. GST pulldown showing an interaction between 35S-radiolabelled ROR(1–523), (1–294) and
(1–235) and glutathione–agarose immobilised GST and GST–MyoD. The input lanes represent ∼10% of the total protein. (D) The C region/DBD of ROR functions
as a dimerization interface. GST pulldown showing an interaction between 35S-radiolabelled ROR(1–523), (1–140) and (1–75) and glutathione–agarose immobilised
GST and GST–MyoD. The input lanes represent ∼10% of the total protein. (E) The ABC region of RORα1 supports the interaction with the N-terminal acid-rich
activation domain of MyoD in vitro. GST pulldown showing an interaction between 35S-radiolabelled ROR(1–235) and (1–140) and glutathione–agarose immobilised
GST, GST–MyoD, GST–MyoD N-terminus, GST–MyoD C-terminus and GST–MyoD bHLH. The input lanes represent ∼10% of the total protein. (F) The DBD of
RORα binds MyoD. GST pulldown showing an interaction between 35S-radiolabelled MyoD with glutathione–agarose immobilised GST, GST–RORα1 and
GST–RORα1(74–139). The input lanes represent ∼10% of the total protein.
several observations, including: (i) the constitutive expression of
RORα1 during myogenesis; (ii) the antagonistic effects of
exogenous Rev-erb α (15) and RVR (16) expression on muscle
differentiation (i.e. the closely related but opposingly acting
orphan nuclear receptors); (iii) the exogenous expression of
dominant negative RVR∆E (16) leading to increased levels of
p21Waf-1/Cip-1 and myogenin mRNAs after serum withdrawal and
precocious biochemical and morphological differentiation.
This study also indicated that closely related orphan nuclear
receptors, RORα, Rev-erbA and RVR, all target expression of the
bHLH proteins, MyoD and myogenin, and the cdk inhibitor p21
during myogenesis (15–17). Rev-erbA and RVR have antagonistic
effects on muscle differentiation, whereas RORα has a positive
influence on myogenesis. The opposing functional roles on
similar gene targets that have critical effects in differentiation
correlates with the contrasting properties of these nuclear
receptors in transcriptional regulation.
Interestingly, exogenous expression of ROR∆E in myogenic
cells leads to repression of endogenous RORα mRNA; this is
identical to the effect of exogenous RVR∆E expression in
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myogenic cells, which resulted in repression of endogenous RVR
mRNA expression. As discussed, this is not unexpected and quite
a common observation in the myogenic system due to the
regulation of mRNA pool sizes by a sensor system in myogenic
cells that is receptive to mRNA produced from the endogenous
and exogenous loci (37,40–44). This process in muscle serves to
make exogenous dominant negative expression vectors quite a
useful tool in the myogenic system because it results in very high
levels of the transfected product relative to the endogenous target.
Rev-erbA and RVR function as dominant repressors of gene
expression, silencing transcription via an interaction with the
nuclear receptor co-repressor, N-CoR (17,50–56). Rev-erbA and
RVR are expressed in proliferating mononucleated myoblasts,
then suppressed during the differentiation of these cells into
post-mitotic multinucleated cells that have acquired the contractile
phenotype. Our study revealed that the cofactor, p300, a functional
integrator/coactivator of diverse signal transactivation pathways
(57), mediated RORα1-dependent transactivation. These
observations are consistent with the functions of the Rev-erb
family and ROR orphan nuclear receptors, as dominant repressors
and activators of transcription, respectively. Furthermore, we
have demonstrated that the N-terminal 149 amino acids of p300
directly interact with the E region of RORα. This correlates with
the requirements for transactivation by this receptor and strongly
suggests that the function of this orphan receptor is modulated by
positive cofactor interactions in vivo. The effect of the dominant
negative expression vector in myogenic cells also correlates with
the inability of this ROR product to interact with p300. Sartorelli
and colleagues have demonstrated that p300 functions as an
essential coactivator for the functions of MyoD and MEF-2
during myogenic conversion and transactivation (29). Puri and
colleagues also demonstrated a requirement for p300 in MyoD-
mediated/dependent cell cycle arrest (30). Subsequently, Puri,
Satorelli and colleagues demonstrated that p300 has a critical role
in the recruitment of the histone acetyltransferase PCAF to the
MyoD regulatory complex (32). These reports support the effects
of the dominant negative ROR construct on MyoD, myogenin
and p21 mRNA expression and the cell cycle.
The regulation of myogenesis (i.e. muscle differentiation) is
intimately controlled by a group of muscle-specific, bHLH
proteins encoded by the myoD gene family (myoD, myogenin,
myf-5 and MRF-4). The products of the myoD gene family are
involved in a variety of protein–protein interactions with many
factors that mediate transcription (e.g. E12 and E47; 18–23),
control the cell cycle (e.g. RB; 58) and regulate chromatin
accessibility and architecture (p300 and PCAF; 29–32). These
protein–protein interactions regulate cellular proliferation and
activate myogenic-specific transcription that results in the
contractile phenotype.
Our study suggests that one of the mechanisms involved in the
functional role of ROR in myogenesis is a direct interaction
between MyoD and RORα1. The interaction is mediated by the
N-terminal activation domain of MyoD (which also mediates
p300 binding) and the C region of ROR that encodes the DBD.
The fact that the DBD (C region) of RORα1 mediates the
interaction with MyoD is novel, and perhaps surprising. However,
during the course of this investigation two other reports have
demonstrated direct interactions between nuclear receptors (RXR
and COUP-TF II) and MyoD (48,47). With respect to the
requirement for the RORα1 DBD as a dimerization interface for
MyoD, it should be mentioned that this domain contains the DR
and T box motifs, which have been implicated as dimerization
interfaces in RXR (and other nuclear receptors). The DR box has
been strongly implicated in the heterodimerization of TR and
RAR with RXR (furthermore, ROR and RAR belong to the same
nuclear receptor sub-family; 59,60). Furthermore, the T box
sequence that forms a third helix in RXR has been implicated in
homo- and heterodimerization (61–65). Recently, COUP-TF II
and SpI have been demonstrated to synergistically regulate
transcription of the HIV type I LTR (66). Consistent with our
observations Rohr et al. demonstrated that the in vitro and in vivo
physical interaction with SpI is mediated by the DBD of COUP-TF.
Moreover, the Octamer transcription factors are recruited by the C
region (DBD) of the glucocorticoid receptor (67) and the RXR DBD
functions as a dimerization interface for PCAF (68).
Although we have demonstrated that MyoD can directly
interact with ROR and p300 and that the bHLH proteins can
simultaneously pulldown the coactivator and the orphan nuclear
receptor, the presence of a ternary complex has not been identified
directly. Furthermore, our investigation did not provide any
indication of competitive binding between these components of
the activation complex. Hence, we propose a structure/model
involving multiple contacts among these components that produces
an active transcription complex that mediates transactivation of
ROR-responsive genes during myogenesis. Finally, it demonstrates
direct crosstalk between the orphan nuclear receptor and bHLH
pathways that has functional consequences for the regulation of
differentiation and phenotypic acquisition. This mode of action and
crosstalk between two central regulatory components may turn out
to be utilised in other pathways of mammalian differentiation.
In conclusion, ROR1-mediated regulation of myogenic trans-
cription involves the cofactor p300 and the bHLH factor MyoD.
Whether direct crosstalk between the orphan nuclear receptor and
bHLH pathways has target gene specificity in a developmental
context remains to be elucidated and will be a focus of future
studies in the context of mammalian differentiation. Current
investigations examining the direct and indirect effects of
RORα1 on the expression of and activity of the promoters of
myoD, myogenin and p21 will hopefully illuminate the entire role
of RORα1 in myogenesis.
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